Special Issue "Viral Hepatitis in Europe: The Unresolved Issues"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 3949
Interests: virology; hepatitis viruses; HBV; viral genetic variability; immune escape; drug resistance; diagnostic methods
Interests: SARS-CoV-2; drug resistance; immune escape; HBV chronic infection; HBV reactivation; hepatocellular carcinoma; HIV; HDV
Special Issues, Collections and Topics in MDPI journals
Special Issue in Vaccines: New Challenges for Natural and Vaccine-Induced Immunity against HBV Infection
Special Issue in Life: An Update on SARS‐CoV‐2: Mutations, Variants, and Their Potential Impact
Special Issue in Viruses: Virological and Immunological Factors Underlying HBV Functional Cure and HBV Reactivation
Hepatitis viruses are estimated to infect between 1.6 and 3.1% of the population in Europe, with their prevalence differing markedly between western and eastern regions. The overall hepatitis morbidity and mortality rates have declined in recent decades due to universal anti-HBV vaccination programs, better surveillance systems, and new efficient therapies. However, there are still significant challenges in the management of viral hepatitis as a result of the high frequency of asymptomatic and often undiagnosed cases, high disease burden in older generations, and the rise in its incidence associated with foreign immigration.
Some of the issues in the management of HCV infection still include difficult-to-treat chronic patients, the development of vaccines and sensitive surveillance diagnostic methods for treated patients, and the availability of screening in populations at a high risk of infection and in resource-limited areas. In HBV infection, the inability to reach sterilizing cures via current therapies has developed the need for new non-invasive biomarkers capable of reflecting the intrahepatic activity of the virus. Extrahepatic manifestations and chronic infection in immunocompromised individuals have identified HEV infection as an emerging health problem, even in regions with sporadic transmission.
This Special Issue invites original research and review articles covering advancements in the diagnosis, prevention, and therapy of viral hepatitis in European countries.
Prof. Dr. Ivana Lazarevic
Dr. Valentina Svicher
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- viral hepatitis
- clinical management
- diagnostic methods
- new biomarkers
- antiviral therapy